Introduction：Basic information about CAS 131875-08-6|Lexacalcitol, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lexacalcitol |
|---|
| CAS Number | 131875-08-6 | Molecular Weight | 460.689 |
|---|
| Density | 1.1±0.1 g/cm3 | Boiling Point | 600.3±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C29H48O4 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 316.8±31.5 °C |
|---|
Names
| Name | (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol |
|---|
| Synonym | More Synonyms |
|---|
Lexacalcitol BiologicalActivity
| Description | Lexacalcitol (KH1060), a vitamin D analog, is potent regulators of cell growth and immune responses. Lexacalcitol can be used for the research of graft rejection, psoriasis, cancer and auto-immune diseases[1][2]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Vitamin D Related >>VD/VDRResearch Areas >>Inflammation/Immunology |
|---|
| In Vitro | Lexacalcitol inhibits cell proliferation by 50% at 10-12 M (14,000 times more active than la,25(OH)2D3) in human histiocytic lymphoma cell line U 937[1]. Lexacalcitol inhibits interleukin-1-induced mouse thymocyte proliferation by 50% at 3×10-16 M , allogeneic stimulation of mouse spleen lymphocytes at 5×10-15 M[1]. |
|---|
| In Vivo | Lexacalcitol (0.5 mg/kg/2 days; i.p.) in combination with cyclosporin A (CyA) can prevent autoimmune destruction of syngeneic islet grafts in spontaneously diabetic NOD recipients[2]. Animal Model: Male and female spontaneously diabetic NOD mice[2] Dosage: 0.5 mg/kg/2 days Administration: Intraperitoneal injection Result: Single treatment with KH1060 or CyA did not result in statistically significant suppression of early graft failure, while the combination of KH1060 and CyA can prevent early graft failure and delay graft rejection of xenogeneic islets in spontaneously diabetic NOD mice. |
|---|
| References | [1]. L Binderup, et al. 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol. 1991 Sep 27;42(8):1569-75. [2]. C Gysemans, et al. A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant Proc. 2001 May;33(3):2365. |
|---|
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|
| Boiling Point | 600.3±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C29H48O4 |
|---|
| Molecular Weight | 460.689 |
|---|
| Flash Point | 316.8±31.5 °C |
|---|
| Exact Mass | 460.355255 |
|---|
| PSA | 69.92000 |
|---|
| LogP | 5.62 |
|---|
| Vapour Pressure | 0.0±3.9 mmHg at 25°C |
|---|
| Index of Refraction | 1.542 |
|---|
| InChIKey | KLZOTDOJMRMLDX-YBBVPDDNSA-N |
|---|
| SMILES | C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)OCCCC(O)(CC)CC)CC(O)CC1O |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| (5Z,7E,20R)-20-((4-Ethyl-4-hydroxyhexyl)oxy)-9,10-secopregna-5,7,10(19)-triene-1a,3b-diol |
| LEVORPHANOL TARTRATE DIHYDRATE |
| (1S-(1a(S*),3ab,4E(1S*,3R*,5Z),7aa))-5-((1-(1-((4-Ethyl-4-hydroxyhexyl)oxy)ethyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-1,3-cyclohexanediol |
| LEVORPHANOL TARTRATE |
| L-3-HYDROXY-N-METHYLMORPHINAN |
| Lexacalcitol |
| LEVORPHANOL TARTRATE SALT |
| Levo-dromoran (tn) |
| Levorphanol Tartrate CII (500 mg) |
| Levorphanol Tartrate (CII),USP |
| 1,3-Cyclohexanediol, 5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-[(4-ethyl-4-hydroxyhexyl)oxy]ethyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)- |
| (1S,3R,5Z,7E,9ξ,20R)-20-[(4-Ethyl-4-hydroxyhexyl)oxy]-9,10-secopregna-5,7,10-triene-1,3-diol |
| 20-epi-22-oxa-24a,26a,27a-tri-homo-1,25-dihydoxyvitamin D3 |
| (1S,3R,5Z,7E,9ξ,20R)-20-[(4-Ethyl-4-hydroxyhexyl)oxy]-9,10-secopregna-5,7,10-trien-1,3-diol |
| UNII:9G3DCA3958 |
| levorphanol tartrate methanol solution |
| LEVORPHANOLTARTRATE,USP |
